Product Description
Mechanisms of Action: CXCR2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Influenza, Human
Phase 1: Inflammation|Chronic Obstructive Pulmonary Disease|Respiratory Tract Infections|Bile Reflux|Respiratory Syncytial Virus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GSK1325756, Phase 2, hospitalised Influenza Patients, RD, NAI co-administration, IV, PKPD | P2 |
Completed |
Influenza, Human |
2019-11-16 |
|
| NCT03170232 | P2 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2018-11-15 |
|
| NCT03250689 | P2 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2018-10-08 |
|
| PH 2a,danirixin vs PBO BD 14days,randomised DB study evaluating the effect on NETs in lungs of COPD | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2018-10-08 |